Effect of angiotensin II type I receptor blocker losartan on bone deterioration in orchiectomized male hypertensive and normotensive rats

Chinese Medical Journal

Volumn 126, Issue 14, 2013, Pages 2661-2665

  Zhang, Ya Feng ^a   Qin, Ling ^a,b   Kwok, Timothy C Y ^b   Yeung, Benson H Y ^b   Li, Guo Dong ^a   Liu, Fan ^a  

^a NANTONG UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiotensin; Angiotensin II type I receptor blocker; Orchidectomy; Osteoporosis; Rat

Indexed keywords

CREATININE; DEOXYPYRIDINOLINE; LOSARTAN; OSTEOCALCIN;

ARTICLE; BLOOD PRESSURE; BONE DENSITY; BONE DISEASE; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); DRUG MEGADOSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERTENSION; LOW DRUG DOSE; MALE; MORPHOMETRICS; NONHUMAN; ORCHIECTOMY; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BONE AND BONES; BONE DENSITY; HYPERTENSION; LOSARTAN; MALE; ORCHIECTOMY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SYSTOLE;

EID: 84880475042     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20121244     Document Type: Article

References (30)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.
2. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep 2008; 10: 92-96.
3. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-589.
4. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE,Browner WS, et al. Beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20: 613-618.
5. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004; 292: 1326-1332.
6. Lynn H, Kwok T, Wong SY, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006; 38: 584-588.
7. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008; 22: 2465-2475.
8. Hiruma Y, Inoue A, Hirose S, Hagiwara H. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun 1997; 230: 176-178.
9. Hagiwara H, Hiruma Y, Inoue A, Yamaguchi A, Hirose S. Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. J Endocrinol 1998; 156: 543-550.
10. Hatton R, Stimpel M, Chambers TJ. Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 1997; 152: 5-10.
11. Broulík PD, Tesar V, Zima T, Jirsa M. Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol Res 2001; 50: 353-358.
12. Ma YF, Stimpel M, Liang H, Pun S, Jee WS. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol 1997; 154: 467-474.
13. Zhou J, Pavel J, Macova M, Yu ZX, Imboden H, Ge L, et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006; 37: 1271-1276.
14. Libouban H, Moreau MF, Legrand E, Baslé MF, Audran M, Chappard D. Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis. Calcif Tissue Int 2001; 68: 31-37.
15. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9: 1643-1649.
16. Zhang G, Qin L, Hung WY, Shi YY, Leung PC, Yeung HY, et al. Flavonoids derived from herbal Epimedium Brevicornum Maxim prevent OVX-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption. Bone 2006; 38: 818-825.
17. Zhang G, Qin L, Shi Y, Leung K. A comparative study between axial compression and lateral fall configuration tested in a rat proximal femur model. Clin Biomech (Bristol, Avon) 2005; 20: 729-735.
18. Egermann M, Goldhahn J, Schneider E. Animal models for fracture treatment in osteoporosis. Osteoporos Int 2005; 16: S129-S138.
19. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27: 282-293.
20. Izawa Y, Sagara K, Kadota T, Makita T. Bone disorders in spontaneously hypertensive rat. Calcif Tissue Int 1985; 37: 605-607.
21. Martin DS, Redetzke R, Vogel E, Mark C, Eyster KM. Effect of ovariectomy on blood pressure and venous tone in female spontaneously hypertensive rats. Am J Hypertens 2008; 21: 983-988.
22. Iliescu R, Cucchiarelli VE, Yanes LL, Iles JW, Reckelhoff JF. Impact of androgen-induced oxidative stress on hypertension in male SHR. Am J Physiol Regul Integr Comp Physiol 2007; 292: R731-R735.
23. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992; 19: 456-463.
24. Silva-Antonialli MM, Tostes RC, Fernandes L, Fior-Chadi DR, Akamine EH, Carvalho MH, et al. A lower ratio of AT1/ AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc Res 2004; 62: 587-593.
25. Lim YK, Retnam L, Bhagavath B, Sethi SK, bin Ali A, Lim SK. Gonadal effects on plasma ACE activity in mice. Atherosclerosis 2002; 160: 311-316.
26. Freshour JR, Chase SE, Vikstrom KL. Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice. Am J Physiol Heart Circ Physiol 2002; 283: H1997-H2003.
27. Lamparter S, Kling L, Schrader M, Ziegler R, Pfeilschifter J. Effects of angiotensin II on bone cells in vitro. J Cell Physiol 1998; 175: 89-98.
28. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 2009; 24: 241-250.
29. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem 2009; 284: 4857-4864.
30. Levy BI. How to explain the differences between rennin angiotensin system modulators. Am J Hypertens 2005; 18: 134S-141S.